快速评估疫苗加强剂οsubvariants

连续突变的严重急性呼吸系统综合症冠状病毒2 (SARS-CoV-2)的严重免疫逃避οsubvariants凸显了需要开发新一代广谱疫苗,特别是高层次的灭活疫苗疫苗接种覆盖率后推进器在中国和许多其他国家。以前,这篇文章的作者开发了冠状病毒疾病2019 (COVID-19)蛋白质亚单位疫苗ZF2001基于串联homo-prototype受体结合域(RBD) SARS-CoV-2飙升的二聚体蛋白质。

抗原被升级成hetero-chimeric原型(PT)β或Delta-BA。1RBD-dimer to broaden the cross-protection efficacy and prove its efficiency with protein subunit and mRNA vaccine platforms. The authors further explore the hetero-chimeric RBD-dimer mRNA vaccines and evaluated their broad-spectrum activities as booster jabs following two doses of inactivated vaccine (IV) in mice.

数据表明,显著提高了中和嵌合疫苗抗体水平对变体和特定的t细胞反应,PT-Beta Delta-BA优越。1RBD as a booster in mice, shedding light on the antigen design for the next generation COVID-19 vaccines. The findings are published in the journal生物安全与健康。